-- 德國藍籌股DAX指數週三收盤上漲2.24%,加入全球股市上漲行列,主要得益於市場對伊朗戰爭可能結束的樂觀情緒重燃。 美國總統川普在宣布暫停護送船隻離開霍爾木茲海峽的行動時,提到在達成最終解決方案方面取得了“巨大進展”,並表示“以觀察能否最終敲定並簽署協議”。路透社引述一位不願透露姓名的巴基斯坦調解員的話報道稱,美巴兩國即將敲定一份旨在停止該地區敵對行動的單頁備忘錄。 在國內,最終商業調查數據顯示,德國私部門近一年來首次萎縮。標普全球數據顯示,德國4月綜合採購經理人指數(PMI)終值從上月的51.9降至48.4,高於48.3的初值。服務業方面,最終PMI為46.9,與初值一致,高於上月的50.9。 「繼4月份服務業業務活動大幅下滑之後,德國經濟在第二季度出現萎縮的可能性有所上升。與製造業在一定程度上受到庫存增加支撐不同,服務業直接受到中東戰爭對需求的衝擊,經歷了近三年半以來最嚴重的下滑,」標普全球市場情報經濟副總監菲爾·史密斯表示。 企業新聞方面,BMW集團(BMW.F)表現突出,收盤上漲5.41%。儘管第一季營收下滑,但加拿大皇家銀行資本市場指出,寶馬汽車業務息稅前利潤(EBIT)好於預期,並重申了2026年全年業績指引,儘管面臨美國最新的關稅威脅。這家德國汽車製造商的營收下降8.1%至310.1億歐元。 儘管近期有消息指出歐盟對美國汽車進口關稅將恢復至25%,但寶馬仍重申了其2026年的業績指引,並預計關稅將對其全年業績產生125個基點的影響。 BMW表示有信心達成協議,並特別預計歐盟對美國進口車的關稅將在2026年下半年降至0%,墨西哥和加拿大的關稅下調也將在2026年下半年生效。研究機構指出:“我們的計算表明,2026年剩餘時間內,寶馬汽車行業的息稅前利潤(EBIT)預期可能會進一步提高。” 大陸集團(CON.F)也是當日表現最佳的股票之一,收盤上漲8.95%。這家德國汽車零件製造商公佈第一季銷售額為 44 億歐元,年減 10.4%,但略高於 43.9 億歐元的普遍預期。儘管地緣政治存在不確定性,該公司仍維持全年營收預期在 173 億歐元至 189 億歐元之間。
Related Articles
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%